Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Globe Newswire•14/08/2026•08:00 ET
0
Whiz Insights
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
LAM-001 Phase 2b data in PH-ILD anticipated in the first quarter of 2028; Phase 2 data in BOS anticipated in the first quarter of 2027
Get started
Create a free account to read the full story.